Changes in the Incidence of Infantile Spinal Muscular Atrophy in Shikoku, Japan between 2011 and 2020

Abstract

by Kentaro Okamoto,Hisahide Nishio,Takahiro Motoki,Toshihiro Jogamoto,Kaori Aibara,Yoichi Kondo,Kentaro Kawamura,Yukihiko Konishi,Chiho Tokorodani,Ritsuo Nishiuchi andMariko Eguchi
Int. J. Neonatal Screen. 2022, 8(4), 52; https://doi.org/10.3390/ijns8040052 - 13 May 2023
Cited by 1 | Viewed by 3088
Abstract
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder. Al-though there was no cure for SMA, newly developed therapeutic drugs (nusinersen, onasemnogene abeparvovec, and risdiplam) have been proven effective for the improvement of motor function and prevention of respiratory insufficiency of infants with SMA. Nusinersen was introduced in Japan in 2017 and onasemnogene abeparvovec in 2020. We hypothesized that the introduction of these drugs might influence the incidence of SMA (more precisely, increase the diagnosis rate of SMA) in Japan. To test this hypothesis, we conducted a second epidemiological study of infantile SMA using questionnaires in Shikoku, Japan between October 2021 and February 2022. The incidence of infantile SMA during the period 2016–2020 was 7.08 (95% confidence interval [CI] 2.45–11.71) per 100,000 live births. According to our previous epidemiological study, the incidence of infantile SMA during 2011–2015 was 2.70 (95% CI 0.05–5.35) per 100,000 live births. The increased incidence of infantile SMA suggests that the widespread news in Japan regarding the introduction of therapeutic agents, nusinersen and onasemnogene abeparvovec, raised clinicians’ awareness about SMA, leading to increased and earlier diagnosis of SMA in Shikoku. Full article
(This article belongs to the Collection Newborn Screening in Japan)
9 pages, 215 KiB
Open AccessCommentary